Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-β k.o. and wild type mice

Journal of Neuroimmunology

Volumn 173, Issue 1-2, 2006, Pages 69-78

  Runström, Anna ^a   Leanderson, Tomas ^a   Ohlsson, Lennart ^a,b   Axelsson, Bengt ^a  

^a Active Biotech Research AB   (Sweden)

^b Box 724   (Sweden)

Author keywords

chEAE; IFN ; IFN k.o.; Laquinimod

Indexed keywords

BETA INTERFERON; LAQUINIMOD;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEMYELINATION; DISEASE COURSE; DRUG INHIBITION; DRUG POTENTIATION; FEMALE; HISTOPATHOLOGY; INFLAMMATORY INFILTRATE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; CENTRAL NERVOUS SYSTEM; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOHISTOCHEMISTRY; INTERFERON-BETA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; POLYMERASE CHAIN REACTION; QUINOLONES;

EID: 33644936033     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2005.11.023     Document Type: Article

References (20)

1. C. Brunmark, A. Runström, L. Ohlsson, B. Sparre, T. Brodin, M. Åström, and G. Hedlund The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis J. Neuroimmunol. 130 2002 163 172
2. L. Erlandsson, R. Blumenthal, M.L. Eloranta, H. Engel, G. Alm, S. Weiss, and T. Leanderson Interferon-β is required for interferon-a production in mouse fibroblasts Curr. Biol. 8 1998 223 226
3. S. Floris, E.L.A. Blezer, G. Schreibelt, E. Döpp, S.M.A. van der Pol, L. Schadee-Eestermans, K. Nicolay, C.D. Dijkstra, and H.E. de Vries Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis. A quantitative MRI study Brain 127 2004 616 627
4. K. Gijbels, S. Engelborghs, and P.P. De Deyn Experimental autoimmune encephalomyelitis: an animal model for multiple sclerosis Neurosci. Res. Commun. 26 2000 193 206
5. C.P. Hawkins, P.M. Munro, F. MacKenzie, J. Kesselring, P.S. Tofts, E.P. du Boulay, D.N. Landon, and W.I. McDonald Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers Brain 113 1990 365 378
6. S. Jönsson, G. Andersson, T. Fex, T. Fristedt, G. Hedlund, K. Jansson, L. Abramo, I. Fritzon, O. Pekarski, A. Runström, H. Sandin, I. Thuvesson, and A. Björk Synthesis and biological evaluation of new 1,2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatments of autoimmune disorders: structure-activity relationship J. Med. Chem. 47 2004 2075 2088
7. D. Katz, J.K. Tauenberger, B. Cannella, D.E. McFarlin, C. Raine, and H.F. McFarland Correlation between magnetic resonance imaging findings and lesion development in multiple sclerosis Ann. Neurol. 34 1993 661 669
8. M.E. Luca, L. Visser, C.J. Lucas, and L. Nagelkerken IFN-β modulates specific T cell responses in vitro but does not affect Experimental Autoimmune Encephalomyelitis in SJL mouse J. Neuroimmunol. 100 1999 190 196
9. 12: treatment to modify notch-1/sonic hedgehog balance J. Immunol. 172 2004 6418 6426
10. b mice: fine specificity and T cell receptor Vβ expression of encephalogenic T cells Eur. J. Immunol. 25 1995 1951 1959
11. C. Polman, F. Barkhof, M. Sandberg-Wollheim, A. Linde, O. Nordle, and T. Nederman Treatment with laquinimod reduces development of active MRI lesions in relapsing multiple sclerosis Neurology 64 2005 987 991
12. R.H. Swanborg Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease Clin. Immunol. Immunopathol. 77 1995 4 13
13. I. Teige, A. Treshow, A. Teige, R. Mattsson, V. Navikas, T. Leanderson, R. Holmdahl, and S. Issazadeh-Navikas IFN-β gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis J. Immunol. 170 2003 4776 4784
14. V.K. Tuohy, M. Yu, L. Yin, P.M. Mathisen, J.M. Johnson, and J.A. Kawczak Modulation of the IL-10/IL-12 cytokine circuit by interferon-β inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis J. Neuroimmunol. 111 2000 55 63
15. H. Tuvesson, I. Hallin, M. Ellman, B. Sparre, P.O. Gunnarsson, and J. Seidegård In vitro metabolism and in vivo pharmacokinetics of quinoline 3-carboxamide derivatives in various species Xenobiotica 35 2005 293 304
16. H. Wiendl, and R. Hohlfeld Therapeutic approaches in multiple sclerosis: lessons and improves from failed and interrupted treatment trials BioDrugs 16 2002 183 200
17. J.S. Yang, L.Y. Xu, B.G. Xiao, P.H. van der Meide, G. Hedlund, and H. Link Laquinimod (ABR-215062) suppresses the development of experimental and autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats J. Neuroimmunol. 156 2004 3 9
18. C.L. Yasuda, A. Al-Sabbagh, E.C. Oliveira, B.M. Diaz-Bardales, A.A. Garcia, and L.M.B. Santos Interferon β modulates experimental autoimmune encephalomyelitis by altering the pattern of cytokine secretion Immunol. Invest. 28 1999 115 126
19. M. Yu, A. Nishiyama, B.D. Trapp, and V.K. Tuohy Interferon-β inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis J. Neuroimunol. 64 1996 91 100
20. L.P Zou, N. Abbas, I. Volkmann, I. Nennesmo, M. Levi, B. Wahren, B. Winblad, G. Hedlund, and J. Zhu Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue Neuropharmacology 42 2002 731 739